Develops an investigational cancer treatment for patients with solid tumors, focusing on recurrent and metastatic head and neck cancer.
10-K for FY2025, filed Mar 23, 2026
Pyxis sells royalty rights and may receive milestone payments based on partners’ performance, plus royalties tied to product sales under collaboration and licensing arrangements.
10-K for FY2025, filed Mar 23, 2026
FY2025 revenue by product or service ↗$13.9M
10-K for FY2025, filed Mar 23, 2026
$13.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Royalty Revenues
Licensed
|
0.0% |
Royalty Revenues, FY2025
$0 Sources
|
Licensed |
|
Sale of Royalty Rights
|
80% |
Sale of Royalty Rights, FY2025
$11M Sources
|
|
|
Milestone Revenue
Sold outright
10-K for FY2025, filed Mar 23, 2026 |
20% |
Milestone Revenue, FY2025
$2.8M Sources
|
Sold outright |
Pyxis works with counterparties to collaboration and licensing arrangements; Merck is a partner in a clinical-trial collaboration. These partners may pay milestone fees and royalties on sales.
No. It lost $79.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$20MView ↗
8-K, filed Sep 8, 2026
On September 4, 2026, the Board of Directors (the “Board”) of Pyxis Oncology, Inc. (the “Company”) appointed Thomas Civik, the Company’s…View ↗
A narrower development focus
The older report described a broad portfolio spanning antibody-drug conjugates, immunotherapy candidates and preclinical antibody discovery. The latest report centers development on MICVO, with a focus on head and neck cancer and combination studies.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 23, 2026
Competes with AbbVie, Abcure, ADC Therapeutics, Alligator Bioscience, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Daiichi Sankyo, Eucure Biopharma, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Lyvgen Biopharma, Nextcure, Pfizer, Philogen, Merck Sharpe & Dohme, Corbus Pharmaceuticals, Rakuten Medical, and Genmab
10-K for FY2025, filed Mar 23, 2026If our product candidate is licensed, it will compete with a range of therapeutic treatments that are either in development or currently…View ↗
Loading...